Director, Market Access Strategy and Value Communications

Role Summary

Director, Market Access Strategy and Value Communications at Intellia Therapeutics, focused on leading strategic and tactical efforts to demonstrate value and facilitate adoption of a late-stage asset for ATTR. Primary responsibility as access launch lead for ATTR with secondary support for the portfolio and pipeline.

Responsibilities

• Access & Value Strategy Development: Lead the creation and execution of comprehensive market access & value strategies that clearly communicate the impact and benefits of Intellia‚Äôs gene editing therapies in ATTR. Develop and refine strategies that align with our commercial goals and resonate in global markets. Support the development of the global commercialization plan, which includes assessing market access favorability across major markets.
• Stakeholder Communication: Develop clear and persuasive communication plans that effectively convey the differentiated value proposition of our therapies. Partner with cross-functional teams, including market access, HEOR, marketing, medical affairs, and corporate communications, to craft narratives that address the needs and interests of clinicians, payers, channel partners, and patient advocacy groups. Identifies evidence enhancements & gaps to inform future research objectives to bolster the value proposition and to support product positioning and aligned access goals.
• Launch & Site Readiness: Develop and refine launch plans and lead execution of market access strategies, access marketing initiatives and corresponding materials/ innovative tactics to ensure launch readiness across all access channels to secure access for providers and patients.
• Market development: Work to establish reimbursement pathways for first-in-class gene therapies across access stakeholders including payer pre-launch engagement plans and site readiness preparation, including supporting marketing programs and communication materials.
• Market Insights & Competitive Intelligence: Leverage insights from the ATTR access & payer landscapes to inform value strategy, messaging, and positioning. Regularly analyze market trends, competitive activity, and regulatory landscape to refine Intellia‚Äôs approach and enhance the launch trajectory. Assess the impact of key policies to the portfolio (e.g. IRA.)
• Pricing & Reimbursement Strategy: Collaborate with market access and HEOR teams to shape pricing and reimbursement strategies, leveraging a deep understanding of gene therapy valuation models. Develop arguments, evidence frameworks and communication materials to support optimal coverage and reimbursement, particularly for novel therapies in rare disease.
• Cross-Functional Leadership: Lead cross-functional initiatives with internal stakeholders to ensure cohesive launch readiness. Act as a primary point of contact for strategic communications efforts related to product value, bridging scientific, commercial, and patient-oriented teams to create unified messages. Effectively leads cross-functionally, particularly across Market Access, HEOR, Brand, Regulatory, and Medical to ensure alignment around, and delivery against, access goals and ensures access view is represented in commercial and development plans, and forecasts.
• Portfolio Support: Provide support for portfolio and pipeline Market Access related activities including, but not limited to payer marketing workstreams, market insights and analytics, congress engagement.

Qualifications

• Proven success in leading value strategy, market access, or strategic communications functions in a launch setting, with demonstrated ability to deliver differentiated and compelling value narratives and customer-facing access marketing materials.
• Track record of effectively launching first in class products in the United States and Global (desired), including pre-launch early payer engagement and market development.
• Experience in developing provider site and channel access & reimbursement strategy in the US and its implementation to support site readiness for product adoption and administration.
• Experience working in commercialization collaborations including co-promotion desired.
• Deep knowledge of healthcare payer systems, reimbursement models ‚Äì including the US buy-and-bill model, and value frameworks, especially in rare disease and Medicare.
• Strong analytical and strategic thinking skills, with a track record of influencing cross-functional teams and external stakeholders.
• Exceptional written and verbal communication skills, with the ability to simplify complex concepts and present confidently to a range of audiences.
• Ability to work effectively in a fast-paced, growth-oriented environment with a commitment to addressing the unique challenges of gene editing therapies.
• Results-driven self-starter with a strong sense of accountability, performance orientation, and the ability to collaborate effectively across functional teams.
• Organized and logical with a high degree of flexibility and adaptability.
• Comfortable navigating ambiguity and shifting priorities, with a high degree of adaptability to pivot as needed.
• Demonstrated flexibility including openness to evolving reporting structures as organization progresses from a one-product to multi-product portfolio company.
• Advanced degree (MBA, PharmD, PhD, MD) or equivalent in business, life sciences, public health, or a related field preferred.
• 8+ years of experience in biopharma, ideally in gene therapy, gene editing, or other innovative therapeutics, with 5+ years in market access and a preference for experience in rare disease and/or cardiovascular.

Skills

• Strategic thinking, cross-functional leadership, stakeholder management
• Excellent written and verbal communication
• Market access, HEOR, pricing and reimbursement strategies
• Global commercialization planning and launch readiness
• Data analysis and insights for value proposition development

Education

• Advanced degree (MBA, PharmD, PhD, MD) or equivalent in business, life sciences, public health, or a related field preferred

Additional Requirements

• Demonstrated flexibility including openness to evolving reporting structures as organization progresses from a one-product to multi-product portfolio company